New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
06:10 EDTAZN, DTVStocks with implied volatility below IV index mean; AZN DTV
Stocks with implied volatility below IV index mean; AstraZeneca (AZN) 25, DirecTV (DTV) 14.
News For AZN;DTV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 28, 2015
07:20 EDTAZNBrookings Institute to hold a public meeting
Subscribe for More Information
July 27, 2015
07:14 EDTDTVAT&T, DirecTV deal conditions look reasonable, says Jefferies
Jefferies says the Federal Communications Commission' conditions for AT&T's (T) pending acquisition of DirecTV appear reasonable and should have a negligible impact on deal economics. The firm sees AT&T's upcoming analyst day in August as a positive catalyst for the shares. It keeps a Buy rating on the stock with a $40 price target.
05:25 EDTAZNGenzyme acquires Caprelsa from AstraZeneca for $300M
Genzyme, a Sanofi (SNY) company, announced that it has entered into a definitive agreement with AstraZeneca (AZN) to acquire Caprelsa, a rare disease therapy, indicated for the treatment of symptomatic or progressive medullary thyroid carcinoma in patients with unresectable locally advanced or metastatic disease. Caprelsa is an oral kinase inhibitor treatment and is currently available in 28 countries. Caprelsa is in Phase III development for differentiated thyroid carcinoma, with the study expected to finish in the second half of 2015. Under the terms of the agreement, Genzyme will pay AstraZeneca up to $300M, including an upfront payment of $165M to acquire the global rights to sell and further develop Caprelsa, and further development and sales milestone payments of up to $135M. The transaction does not include the transfer of any AstraZeneca employees or facilities.
July 24, 2015
17:33 EDTDTVS&P announces changes to S&P 400, 500, and 600 indices
Subscribe for More Information
17:17 EDTDTVSignet Jewelers to replace DirecTV in S&P 500 as of 7/28 close
Subscribe for More Information
16:30 EDTDTVStocks end week lower as Apple headlines busy week of earnings
Subscribe for More Information
16:22 EDTDTVOn The Fly: Top stock stories for Friday
Subscribe for More Information
15:16 EDTDTVAT&T completes acquisition of DirecTV
Subscribe for More Information
14:35 EDTDTVFCC approves, with conditions, AT&T acquisition of DirecTV
Subscribe for More Information
14:32 EDTDTVFCC approves AT&T acquisition of DirecTV
July 23, 2015
19:39 EDTDTVAT&T expecting DirecTV deal approval 'at any time'
On its Q2 earnings conference call, AT&T (T) said it expects "final approval at any time" for the DirecTV (DTV) transaction. The company said it was "very confident" it can make an adequate return on any investment it makes as part of the deal, and that it still fully expects to achieve $2.5B worth of cost synergies from the deal. AT&T said, "We are more confident than ever about the opportunity this transaction brings. We are building a unique communications and entertainment company that we believe will not only transform us but transform our industry as well."
12:39 EDTDTVEarnings Watch: Analyst sentiment positive on AT&T ahead of Q2 results
AT&T (T) is expected to report second quarter earnings after the market close on Thursday, July 23, with a conference call scheduled for 4:30 pm ET. AT&T is a global telecommunications company offering wireless and long distance services. EXPECTATIONS: Analysts are looking for earnings per share of 63c on revenue of $33.04B, according to First Call. The consensus range for EPS is 52c-67c on revenue of $32.51B-$33.84B. LAST QUARTER: AT&T reported first quarter adjusted EPS of 63c against estimates for 62c, on revenue of $32.58B against estimates for $32.84B. In Q1, the company reported the following: Wireless service revenues were down 3.7% to $14.81B; Phone-only postpaid ARPU decreased 9.6% versus the year-earlier quarter; Phone-only postpaid ARPU with AT&T Next monthly billings decreased 1.9% year over year, but increased 0.4% sequentially; Postpaid churn of 1.02%; 6.2M postpaid smartphone gross adds and upgrades in the quarter; 1.2M total wireless net adds, including 441,000 postpaid and 684,000 connected cars; 1.2M branded smartphones added to base, including 700,000 prepaid. AT&T noted its FY15 standalone guidance remained 'on track,' and said it expected the DirecTV (DTV) deal to close in Q2. STREET RESEARCH: Street research has been overwhelmingly positive in the weeks leading up to AT&T's Q2 earnings report with several firms issuing upgrades on the stock. On July 1, Oppenheimer raised their price target on AT&T to $40 from $36. Following AT&T's acquisition of DirecTV, Oppenheimer expects AT&T to benefit from cross-selling, new services, and higher wireless prices. The firm expects the company's free cash flow to be boosted by its winding down of Project VIP. The firm kept an Outperform rating on the stock. Also on July 1, Buckingham initiated AT&T with a Buy rating and $41 price target. On July 9, Stifel resumed coverage of AT&T with a Buy and $41.50 price target. PRICE ACTION: AT&Tís shares are up approximately 4% since the company's Q1 report. However, over the past 12 months, they are down about 5%. In afternoon trading ahead of tonightís Q2 report, AT&Tís shares are down 0.7%.
July 22, 2015
13:58 EDTAZNPiper cuts Array target by only 50c after failed trial
Piper Jaffray analyst Edward Tenthoff says selumetinib for Uveal Melanoma is a small indication and represented only a small part of his valuation for Array BioPharma (ARRY). As such, after partner AstraZeneca (AZN) announced that selumetinib failed in the Phase III trial, the analyst cut his price target for Array by only 50c to $14.50. The primary drivers for Array remain binimetinib and encorafenib in NRAS and BRAF melanoma and low-grade serous ovarian cancer, the analyst tells investors in a research note. He keeps an Overweight rating on the stock.
09:07 EDTAZNOn The Fly: Pre-market Movers
Subscribe for More Information
05:12 EDTAZNAstraZeneca says Phase 3 study of selumetinib did not meet primary endpoint
AstraZeneca (AZN) announced that the Phase 3 SUMIT study of selumetinib in combination with dacarbazine for the treatment of patients with metastatic uveal melanoma did not meet its primary endpoint of progression free survival. This combination therapy showed an adverse event profile generally consistent with current knowledge of the safety profiles of dacarbazine and selumetinib. A full evaluation of the data is ongoing. Selumetinib is a MEK inhibitor in late-stage development, with a primary Phase 3 program in second-line KRAS-mutant advanced non-small cell lung cancer in combination with docetaxel. Selumetinib is also being investigated in a Phase 3 study in differentiated thyroid cancer and in a Phase 2 registration study in patients with neurofibromatosis Type 1. Selumetinib is an oral small molecule MEK inhibitor invented by Array BioPharma (ARRY) and licensed to AstraZeneca in 2003.
July 21, 2015
19:34 EDTDTVAT&T pleased with FCC order, sees closing DirecTV deal 'shortly' after approval
Subscribe for More Information
18:54 EDTDTVAT&T announces Department of Justice completed review of acquisition of DirecTV
AT&T (T) released the following statement "We are pleased the Department of Justice has completed its review of our acquisition of DIRECTV (DTV). We look forward to gaining the approval of the Federal Communications Commission so we can quickly begin providing consumers with the benefits of this combination."
18:33 EDTDTVFCC chairman proposes to approve AT&T-DirecTV deal with conditions
In light of news reports concerning the proposed AT&T (T) and DirecTV (DTV) transaction, FCC chairman Tom Wheeler issued the following statement: "An order recommending that the AT&T-DirecTV transaction be approved with conditions has circulated to the commissioners... If the conditions are approved by my colleagues, 12.5M customer locations will have access to a competitive high-speed fiber connection. This additional build-out is about 10 times the size of AT&Tís current fiber-to-the-premise deployment... and more than triples the number of metropolitan areas AT&T has announced plans to serve. In addition, the conditions will build on the 'Open Internet Order' already in effect... First, in order to prevent discrimination against online video competition, AT&T will not be permitted to exclude affiliated video services and content from data caps on its fixed broadband connections. Second, in order to bring greater transparency to interconnection practices, the company will be required to submit all completed interconnection agreements to the Commission, along with regular reports on network performance... We will require an independent officer to help ensure compliance with these and other proposed conditions." Reference Link
18:24 EDTDTVFCC poised to approve AT&T acquisition of DirecTV, WSJ reports
Subscribe for More Information
16:57 EDTDTVFCC poised to approve AT&T acquisition of DirecTV, DJ says
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use